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P-selectin plays an important role in the development
of various diseases, including atherosclerosis and
thrombosis. In our laboratory we recently identified a
number of specific human P-selectin-binding peptides
containing a Glu-Trp-Val-Asp-Val consensus motif, dis-
playing a low micromolar affinity for P-selectin (IC50 2
M). In search of more potent antagonists for P-selectin,
we have optimized the EWVDV pentapeptide core motif
via a two-step combinatorial chemistry approach. A ded-
icated library of peptide derivatives was generated by
introducing seven substituents at the N and C termini of
the motif. In particular, pentapeptides with gallic acid
or 1,3,5-benzenetricarboxylic acid substituents at the N
terminus proved to be considerably more potent inhib-
itors of P-selectin binding than the parental peptide.
After removal of the N-terminal glutamic acid from the
core sequence, which appeared to be replaceable by a
carboxamide function without loss of affinity, a second
library was synthesized to map the chemical moieties
within the gallic acid or 1,3,5-benzenetricarboxyl acid
groups responsible for the enhanced P-selectin binding.
Moreover, by varying the length and rigidity of the con-
nective spacer, we have further optimized the spatial
orientation of the N-terminal substituent. The combined
use of phage display and subsequent combinatorial
chemistry led to the design of a number of gallic acid-
containing peptides with low nanomolar affinity for
P-selectin both under static and dynamic conditions
(IC50  15.4 nM). These small synthetic antagonists,
which are equally as potent as the natural ligand P-
selectin glycoprotein ligand-1, are promising leads in
anti-atherothrombotic therapy.
P-selectin, a cell adhesion molecule involved in the initial
attachment and “rolling” of leukocytes across the inflamed
vessel wall (1–4), plays a key role in atherosclerosis. In fact,
P-selectin deficiency in mice has been shown to reduce athero-
sclerotic lesion formation (5). Also, P-selectin activation in-
duces hypercoagulance of platelets and mediates platelet-
monocyte aggregation and has thus been associated with
thrombosis (6–9). Therefore, intervention in P-selectin-medi-
ated processes is an attractive therapeutic entry.
The endogenous ligand for P-selectin is P-selectin glycopro-
tein ligand-1 (PSGL-1),1 a 220-kDa disulfide-linked ho-
modimeric sialomucin (10). P-selectin binding to PSGL-1 pro-
ceeds via a short N-terminal amino acid sequence of the latter,
containing three sulfated tyrosines and a sialyl Lewis X (sLeX,
Neu5Ac2–3Gal1–4[Fuc1–3]GlcNAc) moiety (11–14). Most
P-selectin antagonists are carbohydrate derivatives of the sLeX
structure (15). However, as compared with PSGL-1, these gly-
cosides are relatively poor and unselective P-selectin inhibi-
tors, because binding to the other selectin family members (E-
and L-selectin) is equally affected.
In our lab we recently identified, through the use of phage
display, a number of human P-selectin-binding peptides con-
taining an EWVDV pentapeptide consensus motif (16). Binding
of these peptides to human P-selectin was calcium-dependent
and highly specific over E- and L-selectin. With its IC50 of 8 M,
the stripped pentapeptide already appeared to be much more
potent than most of the sLeX-derived carbohydrate ligands. For
therapeutic purposes, however, the affinity of an antagonist
has to be in the low nanomolar range. We obtained this affinity
by tetrameric exposure of the EWVDV peptide on streptavidin
(IC50  2 nM). However, streptavidin-peptide complexes are
rather inadequate for in vivo use, and smaller synthetic leads
are pharmaceutically much more interesting. For this reason
an optimization of the core sequence was performed.
In this paper, we describe the rational design of potent mo-
nomeric P-selectin antagonists using a combinatorial chemis-
try strategy with the consensus motif (E)WVDV as core se-
quence. A structure-activity study yielded a number of peptide
derivatives that are equally as potent as the natural ligand
PSGL-1.
EXPERIMENTAL PROCEDURES
Materials—Fmoc protected amino acids, 1-hydroxybezotriazole
(HOBt), 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetraflu-
oroborate (TBTU), benzotriazol-1-yloxytris(dimethylamino)phos-
phonium hexafluorophosphate (BOP), and 4-hydroxymethylphenoxy-
acetic acid (HMPA) were purchased from Nova Biochem (La¨ufelingen,
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indicate this fact.
§ Member of UNYPHAR, a collaboration between Yamanouchi and
the Universities of Groningen, Leiden, and Utrecht.
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Netherlands. Tel.: 31-71-5276040; Fax: 31-71-5276032; E-mail:
biessen@lacdr.leidenuniv.nl.
1 The abbreviations used are: PSGL-1, P-selectin glycoprotein li-
gand-1; sLeX, sialyl Lewis X; Fmoc, N-(9-fluoroenyl)methoxy-carbonyl;
HOBt, 1-hydroxybezotriazole; TBTU, 2-(1H-benzotriazole-1-yl)-1,1,3,3-
tetramethyluronium tetrafluoroborate; BOP, benzotriazol-1-yloxytris-
(dimethylamino)phosphonium hexafluorophosphate; HMPA, 4-hy-
droxymethylphenoxyacetic acid; Dipea, N,N-diisopropylethylamine;
DMF, N,N-dimethylformamide; TM11-PO, tetrameric complex of bio-
tinylated TM11 with streptavidin peroxidase; HPLC, high performance
liquid chromatography; Boc, N-(t-butoxycarbonyl); DDE, 4,4-dimethyl-
2,6-dioxocyclohex-1-ylidene)ethyl; CHO, Chinese hamster ovary;
CHO-P, CHO cells expressing P-selectin; PAA, polyacrylamide; Lea,
Lewis A; AM, acetoxymethyl.
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Switzerland), except Fmoc-4-aminobenzoic acid, Fmoc-(4-aminomethyl)-
benzoic acid, and Fmoc-tranexamic acid, which were from Neosystem
(Strasbourg, France). Trifluoroacetic acid, N,N-diisopropylethylamine
(Dipea), dichloromethane, dichloroethane, N,N-dimethylformamide
(DMF), piperidine, and 1-methyl-2-pyrrolidine were of peptide grade
and purchased from Biosolve (Valkenswaard, The Netherlands). 4-Di-
methylaminopyridine was obtained from Janssen (Beersse, Belgium).
N,N-dicyclohexylcarbodiimide, hydrazine monohydrate, and all of
the carboxylic acids were obtained from Acros (Hertogenbosch, The
Netherlands). N-Methylmorpholine was obtained from Fluka (Buchs,
Switzerland). Tentagel S-NH2 (0.26 mmol/g) was from Rapp Polymer
(Tu¨bingen, Germany). Triisopropylsilane, goat anti-human IgG (Fc-
specific), and bovine serum albumin were from Sigma-Aldrich. TM11-
biotin (biotin-CDVEWVDVSSLEWDLPC) was synthesized by Dr. Van
der Zee (Department of Immunology, Utrecht, The Netherlands).
Human P-selectin/IgG-Fc and human E-selectin/IgG-Fc chimeras were
kindly provided by Drs. Appelmelk and Van Dijk (Free University of
Amsterdam, Amsterdam, The Netherlands). Human L-selectin and
mouse P-selectin were purchased by R&D Systems Europe, Ltd.
(Abingdon, UK). Streptavidin peroxidase was obtained from Amersham
Biosciences, and biotin-PAA-Lea-SO3H was from Synthesome
(Mu¨nchen, Germany). 3,3,5,5-Tetramethylbenzine/H2O2 was obtained
from Pierce. RPMI 1640 medium, Dulbecco’s modified Eagle’s medium,
fetal calf serum, and penicillin/streptomycin were obtained from Bio-
Whittaker Europe (Verviers, Belgium).
Chemical Synthesis of Resin-bound Core Sequence 9—Core se-
quence 9 FmocHN-Glu(OtBu)-Trp(Boc)-Val-Asp(OtBu)-Val-Lys-
(DDE)--aminobutyric acid-HMPA-resin was synthesized on an Ap-
plied Biosystems 9050 peptide synthesizer (Warrington, UK) using
standard Fmoc chemistry. In short, Tentagel S-NH2 (load 0.26
mmol/g) was provided with HMPA as a linker, resulting in resin 8.
Fmoc--aminobutyric acid-OH (10 eq) was attached to the HMPA
resin 8 under the agency of N,N-dicyclohexylcarbodiimide (5 eq) and
4-dimethylaminopyridine (0.5 eq). All other amino acids, with acid-
labile side chain protection if necessary, were attached by coupling in
the presence of HOBt/TBTU/Dipea (4, 4, and 8 eq, respectively). After
coupling, the resin was washed with DMF, iso-propanol, and diethyl
ether and subsequently dried.
Synthesis of Library 10—The solid phase synthesis of library 10 was
performed using a Flexchem© system (Robbins Scientific). After re-
moval of the N-terminal Fmoc group of sequence 9 by 20% piperidine in
DMF, the resin was washed (in DMF) and dried. The resin was distrib-
uted in 10-mg quantities over a solvent-resistant 48-well filter plate.
After washing with DMF, a mixture of the desired carboxylic acid (40
eq), BOP (20 eq), HOBt (20 eq), and N-methylmorpholine (100 eq) was
added (total volume, 300 l), and the suspended resin was incubated for
3 h. Subsequently, the resin was washed with DMF and incubated three
times for 3 min with hydrazine monohydrate (2% in DMF) to remove the
DDE group. After washing with DMF, a mixture of the second carbox-
ylic acid, BOP, HOBt, and N-methylmorpholine (same amounts as
described above) was added and once again incubated for 3 h. Peptides,
which were only modified at the C-terminal lysine (peptides HP01–
HP07), were first N-bocylated with di-tert-butyl-dicarbonate (0.25 M)
and Dipea (0.125 M) in 1-methyl-2-pyrrolidine to protect the N-terminal
amine function. After removal of the solvent, the peptides were cleaved
off from the resin with a trifluoroacetic acid, triisopropylsilane, and
water mixture (95:2.5:2.5, v/v/v). Each sample was lyophilized and
stored at 20 °C until use.
Synthesis of Peptides 11–13, Library 14, and Peptides 27–33—Pep-
tides 11–13, library 14, and peptides 27–33 were prepared in the same
manner as described for library 10 from resin bound core sequence
FmocHN-Trp(Boc)-Val-Asp(OtBu)-Val-HMPA-resin. Peptide 11 was
acetylated using acetic anhydride (0.25 M) and Dipea (0.125 M) in
1-methyl-2-pyrrolidine.
Preparation of Samples and Determination of Peptide Concentra-
tion—Lyophilized peptides were dissolved in ammonia (100 mM, 100 l)
and aqueous ammonium bicarbonate solution (5 mM, 400 l). The
peptide concentration was determined spectrophotometrically at 280
nm (tryptophan;   5.5 mM1 cm1). Absorptions were corrected for
the absorption coefficient of the introduced carboxylic acid(s). Com-
pound purity was checked randomly (10% of all compounds) by
HPLC analysis on a C8 or C18 reversed phase column (Alltech, Breda,
The Netherlands) using an acetonitrile/water gradient with 0.1% trif-
luoroacetic acid at 280 nm and by matrix-assisted laser desorption
ionization mass spectrometry. Compounds in Tables I and II were all
purified by HPLC analysis (90%) and analyzed by mass spectrometry.
Competition Assay with TM11-PO or Biotin-PAA-Lea-SO3—The pep-
tides were assayed for their ability to inhibit TM11-PO binding to
human P-selectin (16) or biotin-PAA-Lea-SO3H binding to human and
mouse P-selectin and human E- and L-selectin (17). TM11-PO, a tet-
rameric TM11/streptavidin peroxidase complex, were freshly prepared
by incubating streptavidin peroxidase (8.4 l, 2.0 M) and TM11-biotin
(biotin-CDVEWVDVSSLEWDLPC, 1.5 l, 190 mM) for 2 h at room
temperature in assay buffer. For competition studies, a 96-well micro-
titer plate (high binding, flat bottom; Costar, Corning, NY) was coated
overnight at 4 °C with 10 g/ml goat anti-human IgG in coating buffer
(50 mM NaHCO3, pH 9.6). Subsequently, the wells were washed with
assay buffer (20 mM HEPES, 150 mM NaCl, 1 mM CaCl2, pH 7.4) and
incubated for 1 h at 37 °C with blocking buffer (3% bovine serum
albumin in assay buffer). After washing with assay buffer, the wells
were incubated for 2 h at 37 °C with human P-selectin/IgG-Fc (0.3
g/ml). Subsequently, the wells were washed with assay buffer and
incubated for 1 h at 4 °C with the TM11-PO complex or biotin-PAA-Lea-
SO3. The wells were washed six times with washing buffer (0.1% Tween
20 in assay buffer). 3,3,5,5-Tetramethylbenzine/H2O2 was added, and
the wells were incubated at room temperature for 15 min. The reaction
was halted by the addition of 2 M H2SO4, and the absorbance was
measured at 450 nm.
HL60 Adhesion Assay—HL60 cells were fluorescently labeled by
incubation for 30 min at 37 °C with 5 M calcein-AM (Molecular Probes,
Leiden, The Netherlands) in RPMI. These cells (50,000/well) were
added to cultured CHO cells expressing P-selectin (CHO-P cells, cul-
tured in Dulbecco’s modified Eagle’s medium with 10% fetal calf serum,
5 mM nonessential amino acids, 5 mM L-glutamine, and 20,000 units of
penicillin/streptomycin), seeded in 96-well plates in the presence or
absence of the P-selectin antagonists (1h, 4 °C) (16). After gentle wash-
ing with RPMI, CHO-P-associated fluorescence was measured (exc 
485, em  530 nm).
Flow Chamber and Perfusion Studies—Dynamic interactions be-
tween HL60 cells and CHO-P cells monolayers grown onto glass cover-
slips coated with 30 g/ml collagen (collagen S type I; Roche Diagno-
sis, Brussel, Belgium) were analyzed in a parallel plate perfusion
chamber as described (18), with some modifications. The coverslip
constituted the bottom of the chamber, and the actual chamber was
formed by a 254-m height silicon rubber gasket designed with a
conically shaped flow path, thus resulting in a 3-fold increase of wall
shear rate from the inlet of the chamber to the outlet. Calcein-AM-
labeled HL60 cells suspended in RPMI (0.5  106/ml) were perfused
at 37 °C with an inverted syringe pump (Harvard Instruments, South
Natick, MA) at a flow rate of 1 ml/min. By mounting the flow chamber
on the table of an inverted epifluorescence microscope (Diaphot;
Nikon, Melville, NY) coupled to a Cohu CCD video camera (COHU
Inc., San Diego, CA), HL60 cells translocation over CHO-P monolay-
ers were observed at wall shear rates of 300 and 600 s1, in the
presence or absence of P-selectin antagonists added to HL60 suspen-
sions 2 min before the onset of perfusion. Real time movies of 12 s (10
images/s), recorded at random positions in the flow path correspond-
ing to chosen wall shear rates were stored into the memory of an
attached computer and digitized with a Scion LG3 frame grabber
(Scion Corp, Frederick, MD). The velocity of HL60 cells rolling over
the CHO-P cells was determined by measuring the distance traveled
by the HL60 cells during at least 1 s of flow, using the NIH Image
program, version 6.1.
RESULTS
In pursuit of P-selectin antagonists for intervention in in-
flammatory diseases such as atherosclerosis, a cysteine-con-
strained phage-displayed peptide library was screened for P-
selectin binders (16). A number of positive clones, including
TM11, were identified and sequenced for their peptide insert
(Table I). Comparison of the peptides for sequence homology
revealed a pentapeptide consensus motif, which was estab-
lished to be critical for human P-selectin binding by subsequent
truncation and alanine scanning: EWVDV. With its low micro-
molar affinity, we argued that the therapeutic potential of the
EWVDV peptide would greatly benefit from further optimiza-
tion studies.
Instead of conventional replacement of individual amino ac-
ids by naturally occurring amino acids, we preferred introduc-
tion of new chemical entities within the EWVDV core sequence
by acylation of available amine groups to enhance the affinity
for P-selectin. This flexible strategy enables the introduction of
an infinite range of substituents and already has been shown
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effective for the optimization of an SH2 binding peptide by Yeh
et al. (19). Although Yeh et al. used a vast peptide library (103
peptides) for screening, we considered a stepwise optimization
protocol on the basis of dedicated libraries of approximately
100 EWVDV analogues to be at least equally effective and more
practical. In the first screening step we have addressed the
effect of substituting the N and C termini of the EWVDV motif
with seven different moieties (Fig. 1, acyl moieties 1–7), result-
ing in a library of 63 compounds.
The N-terminal amine group within the peptide was readily
available for coupling to the carboxylic acids after removal of
the protecting Fmoc group. To enable modification at the C
terminus, however, a DDE-protected lysine was introduced
behind the last valine of the core peptide. The DDE group can
be selectively removed with 2% hydrazine without affecting the
acid-labile side chain protecting groups (20), thus allowing
independent introduction of substituents at either site of the
peptide. Starting from Tentagel S-NH2 resin with an acid-
labile HMPA linker (resin 8), core sequence 9 was synthesized
using HOBt/TBTU/Dipea couplings. The first amino acid,
-aminobutyric acid, was introduced to increase the distance
between the C-terminal carboxylic acid and the amine function
of the lysine. After the introduction of carboxylic acids 1–7,
library 10 was cleaved from the resin by incubation with a
FIG. 1. Chemical structures of acyl moieties introduced to core
sequence 10.
FIG. 2. Solid phase synthesis of library 10. Core sequence 10 was
synthesized using standard Fmoc chemistry on Tentagel S-NH2 resin
with HMPA linker (sequence 9). The core peptide was then derivatized
at the N terminus (after removal of the Fmoc) or on the C terminus
(after selective removal of the DDE group by 2% hydrazine) with seven
different carboxylic acids (see Fig. 1). The peptides were liberated from
the resin by trifluoroacetic acid cleavage, resulting in library 10. tBu,
tert-butyl; TFA, trifluoroacetic acid.
FIG. 3. Ability of peptides HP10-
HP77 to inhibit ligand binding to hu-
man P-selectin. The crude peptides
were tested in a competition assay for
their ability to displace binding of
TM11-PO to human P-selectin. Each bar
represents the binding of TM11-PO in the
presence of peptide (5 M, n  3–5 
S.E.). The peptides are coded HPij, where
i and j refer to the acyl moiety attached to
the N and C termini, respectively. The
N/C-terminally unmodified amino group
is indicated by 0.
TABLE I
Peptides and their affinities for human P-selectin as determined by
competition enzyme-linked immunosorbent assay
Peptide Sequence IC50
a
M
TM11 CDVEWVDVSSLEWDLPC 2b
EWVDV 8b
DWVDV 16b
KWVDV 28b
AWVDV 27b
WVDV 1000b
11 Ac-WVDV 27
12 GA-WVDV 0.037
13 GA-EWVDV 0.031
a The results are the averages of at least three experiments at eight
different concentrations of peptide as determined in TM11-PO compe-
tition ELISA (see “Experimental Procedures”).
b From Molenaar et al. (16).
Optimization of a P-selectin-binding Peptide 10203
 at W
A
LA
EU
S LIBRA
RY
 on M
ay 3, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
trifluoroacetic acid/triisopropylsilane/H2O mixture (Fig. 2). To
elucidate peptides with enhanced P-selectin binding as com-
pared with the EWVDV core, all of the crude peptides were
tested below the IC50 of the EWVDV peptide (IC50  6 M) at 5
M in a competition assay for binding TM11-PO to P-selectin
(Fig. 3). This complex was previously shown to be a potent and
specific ligand for P-selectin (16). Peptides with N-terminal
1,3,5-tricarboxylic acid (acyl moiety 1) or gallic acid (acyl moi-
ety 6) substituents were found to be most effective in inhibiting
P-selectin binding:  90% as compared with only 35% for the
unsubstituted reference. The C-terminal counterparts, pep-
tides HP01 and HP06, were considerably less effective,
whereas the disubstituted peptides HP11 and HP66 were
equally as potent as the N-terminal monosubstituted peptides
HP10 and HP60 (peptides are coded HPij, where i and j refer to
the acyl moieties attached to the N and C termini, respectively;
N/C-terminally unmodified amino group is indicated by 0).
Therefore, for the second optimization step we shifted our
attention to the N-terminal substitution, thus obviating the
introduction of a potentially perturbing lysine group at the
C-terminal end.
Earlier observations already suggested that the N-terminal
amide function rather than the complete glutamic acid moiety
is necessary for potent P-selectin binding (16). Peptides
KWVDV and AWVDV were equally potent inhibitors of P-
selectin binding, but the absence of an N-terminal amide func-
tion (WVDV) led to a complete loss in binding capacity (Table
I). To conclusively demonstrate the involvement of the amide
group in P-selectin binding, we have synthesized Ac-WVDV
(Peptide 11). Indeed, Ac-WVDV was found to inhibit P-selectin
binding at a similar potency as the core sequence EWVDV.
Likewise, when gallic acid (acyl moiety 6), the most potent
substituent of the first library, was attached directly to the
-amine group of WVDV (peptide 12), this had similar potency
as when the longer EWVDV core was used instead (peptide 13)
(IC50  37 versus 31 nM, respectively).
On the basis of the above findings, a new library of 42
substituted WVDV peptides was designed (Fig. 4A, library 14).
This dedicated library served two purposes. First, the length
and flexibility of the linker between the N-terminal substituent
group and the WVDV motif were varied to optimize the spatial
orientation of the substituent. Carboxylic acids R3 were at-
tached directly to the -amino group of the WVDV core or via a
glycine or aminobutyric acid spacer (linkers R4). Second, to be
able to pinpoint the actual groups within 1,3,5-benzene carbox-
ylic acid and gallic acid responsible for the enhanced affinity of
peptides HP10 and HP60, several carboxylic acids resembling
these carboxylic acids were introduced at the N-terminal amine
(carboxylic acids R3).
In addition, a range of other anionic substituents was intro-
duced to mimic the negatively charged tyrosine sulfates and
the neuraminic acid of sLeX of PSGL-1. These moieties have
been shown to be crucial for high P-selectin binding, possibly
through occupation of a second binding site on P-selectin (12,
21, 22). Because a number of peptides from library 10 could
displace TM11-PO binding above 90% at a 5 M concentration,
the peptides from library 14 were tested at 1 M. At this
concentration, L-cysteic acid-derived (acyl moiety 15) and 5-sul-
fosalicyclic acid-derived (acyl moiety 16) peptides gave up to
40% inhibition of TM11-PO binding, which is comparable with
the 1,3,5-benzenetricarboxylic acid-derivatized peptides (acyl
moiety 1) (Fig. 4B). Attachment of nitroaryl (acyl moiety 17) or
fluoroaryl groups (acyl moiety 18) resulted in peptides equally
as potent as EWVDV, displaying a nonsignificant 5% inhibition
at this concentration.
Removal of one of the carboxyl acids of substituent 1, by
FIG. 4. Chemical structure and biological activity of library 14.
A, chemical structure of compounds from library 14. B–D, members of
crude peptide library 14 (1 M) were tested in a competition assay of
TM11-PO binding to human P-selectin. Three different spacers between
the acyl moiety and the WVDV core sequence were used (R4): no spacer
(white bars), a glycyl spacer (hatched bars), and amino butyric spacer
(black bars). The chemical structures of the introduced acyl modifica-
tions (R1) are depicted below these bars.
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introduction of carboxylic acids 19–21, did not considerably
reduce the affinity for P-selectin, regardless of the position and
flexibility of the remaining groups (Fig. 4C). Replacement of
the carboxylic acid by an hydroxyl group (carboxylic acid 1 by
22) did not influence P-selectin binding either, suggesting that
the gain in affinity is mediated by hydrogen bridging rather
than electrostatic interactions. Contrary to the effect of the
carboxylic acids, the number of exposed hydroxyls appear to be
critical for its affinity, because monobenzoic acid-derivatized
(acids 23 and 24) and dihydroxybenzoic acid-derivatized (acid
25) peptides were much less effective than the trihydoxylated
counterparts (1) (Fig. 4D). Importantly, P-selectin binding was
completely abolished after conversion of the hydroxyls into
methyl ethers (via introduction of acid 26).
The spacer length R4 between the core motif and the substit-
uent was of little influence. IC50 values for the peptides lacking
an intermediate spacer or having a glycyl or amino buryrate
spacer (peptides 12, 27, and 28, respectively) ranged from 37.1
to 15.4 nM (Table II). Further elongation of the spacer, however,
to an amino hexanoate (C-6) (peptide 29) caused a significant
decrease in affinity (IC50  62.9 nM).
Because flexible spacers confer the advantage of minimal
conformational constraints but at the same time cause a max-
imal loss in entropy after binding, it is preferable to insert a
more rigid spacer between the substituent and the core motif,
when possible. To investigate the effect of spacer flexibility on
the affinity of the substituted peptides for P-selectin, we there-
fore introduced a number of equally sized, more rigid ana-
logues. A cyclic L-proline linker (peptide 30) led to a 5-fold
reduction of the IC50 to 250 nM. Use of a linear 4-amino ben-
zoate spacer, which is conformationally locked and only allows
axial rotation of the gallic acid moiety (peptide 31), let to a
complete loss in affinity (1000 nM). Interestingly, binding is
partially recovered when inserting an additional CH2 group
between linker and gallic acid (peptide 32), regardless of
FIG. 5. Competition of biotin-PAA-Lea-SO3 binding to human
P-selectin (f), mouse P-selectin (), human L-selectin (Œ), and
human E-selectin () by peptide 28. The wells were coated with
each selectin (0.3 g/ml) and incubated with 0.33 g/ml biotin-PAA-
Lea-SO3 with or without peptide 28 as described in under “Experimen-
tal Procedures.” The values represent the means of triplicate experi-
ments  S.E.
FIG. 6. Competition of HL60 cell binding to CHO-P cells by
peptide 28 (f) or EWVDV (). CHO-P cells seeded in 96 wells were
incubated with calcein-labeled HL60 cells in the presence of peptide 28
or EWVDV. The values represent means of triplicate experiments 
S.E.
FIG. 7. HL60 rolling velocities in flow chamber perfusion ex-
periments. The velocity (m/s) of calcein-AM-labeled HL60 cells roll-
ing over CHO-P cell-coated coverslips at wall shear rates of 300 s1
(white bars) and 600 s1 (black bars), in the absence (control) or pres-
ence of peptide 28 (5, 50, and 500 nM) or EWVDV (500 nM)) was
determined from real time movies. For each condition the velocity of at
least 20 individual HL60 cells was measured in three to nine independ-
ent perfusion assays. The values represent the means  S.E. of rolling
velocities. no tethering means a too short contact time ( 0.1 s) between
HL60 cells and CHO-P monolayers to allow velocity measurement.
TABLE II
Gallic acid-derivatized peptides and their IC50 for human P-selectin
as determined by competition enzyme-linked immunosorbent assay
a The values are the means of at least three experiments at eight
different concentrations of peptide as determined in TM11-PO compe-
tition enzyme-linked immunosorbent assay (see “Experimental Proce-
dures”).
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whether the cyclohexyl group is plain aromatic (phenyl; peptide
32) or chair/boat configured (cyclohexyl; peptide 33).
Introduction of the gallic acid moiety did not influence the
specificity of the peptides. Peptide 28, the most potent antag-
onist of this series, did not displace biotin-PAA-Lea-SO3H bind-
ing to either mouse P-selectin or human E- and L-selectin (Fig.
5). This PAA-based conjugate of sulfated Lea was reported to
bind with low nanomolar affinity to all selectins (17).
Finally, we investigated peptide 28 for its ability to inhibit
HL60 cell adhesion to P-selectin-transfected CHO cells
(CHO-P cells) under static (Fig. 6) and flow conditions (Fig.
7). Monocyte-derived HL60 cells have a high expression of
PSGL-1 (10, 23) and are adherent to CHO-P cells. Peptide 28
was found to inhibit HL60 cell adhesion with an EC50 of 74
nM, indicating that it is an effective inhibitor of human P-
selectin in a more physiological setting. Under flow condi-
tions, the peptide significantly increased the rolling velocity
of HL60 cells at concentrations as low as 50 nM, indicating a
reduced interaction between PSGL-1 and P-selectin. Surpris-
ingly, at 500 nM tethering to and rolling of HL60 cells along
P-selectin expressing cells could be observed. This is in sharp
contrast to the unmodified EWVDV peptide, which was un-
able to affect the rolling velocity or cell adhesion at the same
concentration.
DISCUSSION
The use of phage display in ligand discovery has been
shown to be very effective over the last decade, in particular
for ill-defined targets (24, 25). Despite its apparent promise
for the identification of peptide motifs as initial leads, phage
display-based drug design has a number of setbacks. Derived
leads often display affinity in the micromolar to millimolar
range, which precludes direct use in a therapeutic setting. In
addition phage display does not allow the introduction of
unnatural amino acid derivatives or post-translational mod-
ifications. A conventional strategy to increase the affinity of
the peptide ligands involves the systematic replacement of
amino acids after having identified a minimal effective motif
via alanine scanning and truncation studies (26, 27). An
integrated approach in which lead peptides are optimized
using combinatorial organic chemistry on the other hand will
pave the way for non-amino acid modifications of the peptide
leads and will greatly increase the number of possible
substituents.
The most convenient way to introduce these modifications
and to generate large compound libraries involves the use of
solid phase combinatorial chemistry. However, the synthesis of
large peptide libraries puts serious demands on purification
and screening of compounds to render the process viable. Small
dedicated libraries of compounds with a stepwise approach
may likely be equally effective for enhancing target affinity.
In this study we have taken a phage display-derived peptide
(16) as a starting point for organic chemical optimization. This
EWVDV pentapeptide was shown to specifically bind to P-
selectin and antagonized HL60 adhesion to P-selectin-trans-
fected cells. In a first library, seven different substituents were
introduced by acylation of primary amine groups at either the
N or C terminus. Affinity testing of the crude peptides, at a
concentration just below the IC50 of the parental EWVDV pep-
tide to reduce the number of hits (5 M), revealed that N-
terminal modification with 1,3,5-tricarboxybenzoic acid (car-
boxylic acid 1) or gallic acid (carboxylic acid 6) were most
effective in inhibiting P-selectin binding (90% inhibition ver-
sus 30% for the underivatized peptide). C terminus modifica-
tions had little to no influence on the affinity of the core
peptide.
The core peptide could even be reduced to WVDV after iden-
tification that the N-terminal amide rather than the glutamic
acid was imperative for P-selectin binding. However, when a
negatively charged Glu or Asp before the WVDV was present,
P-selectin binding was slightly improved compared with other
uncharged amino acids like Ala and Lys. Negatively charged
groups within PSGL-1, i.e. tyrosine sulfates and the neura-
minic acid of sLeX, are found to be crucial for P-selectin binding
(11–14). This might imply that negatively charged amino acids
Glu and Asp interact with P-selectin at a site proximal to the
actual sLeX-binding site. Indeed the existence of a second bind-
ing pocket has already been speculated upon in a number of
reports (12, 21, 22), although solid evidence still remains to be
provided. The derivatization of the core peptide with the gallic
acid substituent, again the best substituent in our second li-
brary, would also allow occupation of both binding sites, thus
explaining the considerably increased affinity.
Of the introduced spacers, the elongated aminobutyric acid
spacer performed best (peptide 28, IC50  15.4 nM). Introduc-
tion of longer or more rigid spacers led to a considerable loss in
affinity, indicating that the spatial orientation of the terminal
gallic acid group with respect to the peptide is critical. Peptide
28 was also tested for its ability to antagonize HL60 adhesion
to P-selectin under both static and dynamic conditions. PSGL-
1-mediated adhesion to P-selectin was impaired at 50 nM and
even completely blocked at 500 nM.
In conclusion, we show in this study that stepwise optimi-
zation of peptide leads through dedicated small peptide li-
braries is a very efficient strategy. The affinity of the P-
selectin binding sequence (E)WVDV was increased almost
800-fold via the introduction of a gallic acid moiety at the N
terminus, as was shown in different testing systems. Thus,
the combined use of phage display and subsequent combina-
torial chemistry led to the design of P-selectin antagonists
with nanomolar affinity. These small synthetic antagonists,
which are equally potent as the natural ligand P-selectin
glycoprotein ligand-1, may be promising leads in athero-
thrombotic therapy.
For further in vivo use we plan to alter the pharmacokinetic
profile of these compounds. Shifting our attention from pep-
tides to peptidomimics would also decrease the susceptibility to
proteases. This work is currently in progress.
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